EAM Investors LLC Sells 4,964 Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS)

EAM Investors LLC cut its stake in Sensus Healthcare, Inc. (NASDAQ:SRTS) by 5.1% in the fourth quarter, HoldingsChannel reports. The fund owned 92,103 shares of the company’s stock after selling 4,964 shares during the period. EAM Investors LLC’s holdings in Sensus Healthcare were worth $637,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. JPMorgan Chase & Co. bought a new position in Sensus Healthcare in the 4th quarter worth approximately $27,000. Barclays PLC acquired a new position in shares of Sensus Healthcare during the fourth quarter valued at $35,000. IFP Advisors Inc bought a new position in Sensus Healthcare in the fourth quarter valued at about $95,000. CreativeOne Wealth LLC acquired a new stake in Sensus Healthcare in the fourth quarter worth about $155,000. Finally, XTX Topco Ltd raised its holdings in Sensus Healthcare by 76.0% during the 3rd quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock worth $183,000 after purchasing an additional 13,619 shares during the last quarter. 25.30% of the stock is currently owned by institutional investors and hedge funds.

Sensus Healthcare Stock Performance

Shares of SRTS opened at $4.59 on Friday. The firm has a market cap of $75.71 million, a P/E ratio of 11.48 and a beta of 1.11. Sensus Healthcare, Inc. has a twelve month low of $3.16 and a twelve month high of $9.33. The firm’s 50 day moving average price is $4.85 and its two-hundred day moving average price is $6.41.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. On average, sell-side analysts anticipate that Sensus Healthcare, Inc. will post 0.32 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SRTS has been the topic of several recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Sensus Healthcare in a research note on Friday, April 4th. Lake Street Capital decreased their price target on shares of Sensus Healthcare from $18.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, March 11th.

Sensus Healthcare Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.